Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021


HomeeMIRAmed USAThe MIRApeel™ Fractional Transbrasion System Launches in the USA

The MIRApeel™ Fractional Transbrasion System Launches in the USA

As reported by eMIRAmed USA, LLC, MIRApeel™, is an aesthetic device which uses a new comprehensive 3D Skin Desquamation technology called “Fractional Transbrasion” to address a range of visible skin issues and the effects of premature aging.

Skincare professionals will experience a hands-on demonstration of just what sets this system apart at the American Academy of Dermatology meeting.  This latest skin rejuvenation technology was first developed and introduced in Germany and has quickly gained credibility among early-adopting dermatologists throughout Europe. This success led to a strong interest in the United States which caused the makers to accelerate their plans to register with the US FDA and make this system available here.

“The 2018 Annual Meeting of The American Academy of Dermatology is the perfect forum to showcase the comprehensive patient and client socio-demographic range, encompassing different skin types and skin conditions that can be directly addressed and improved with the MIRApeel™ treatments.

“The MIRA high-tech benefits of faster treatment sessions is more convenient and comfortable for clients and increases their satisfaction which readily translates into faster monetization and return on investment for users.”

“The real and most distinctive features of this offering are the MIRArollers – the special wet micro-needles – the MIRAbrasor and the serums,” says Serge Castro, President of eMIRAmed USA, LLC.

“We are ready to fully explore expanded distribution channels, build our sales presence, and strike meaningful associations with complementary aesthetic product manufacturers.”

“The new MIRApeel™  is being experienced by a growing number of patients, clients and physicians across Europe and will be presented to physicians during the AAD meetings as well.”

The MIRA family of technologies includes the MIRApeel™, the newly developed MIRAbrasor™ and MIRAroller™ attachments and a series of MIRAjolie™ serums. This range will be exclusively available to dermatology, cosmetic surgery and medical spa physicians throughout the United States.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy